| Document |
Document Title |
|
JP7335275B2 |
The application relates to a compound having Formula Ia or Ib: or a pharmaceutically acceptable salt, hydrate, or solvate thereof, which modulates the activity of EGFR, a pharmaceutical composition comprising the compound, and a method o...
|
|
JP2023535492A |
The present invention relates to compounds of general formula I [Chemical 1] where R1‐7, Hy and X are as defined in claim 1. Such compounds of general formula I bind to VDAC1 and are suitable for use in methods of treating diabetes or ...
|
|
JP7322151B2 |
This invention relates to a crystalline form of the Compound (I), wherein the crystalline form displays its strongest reflection, stated as a 2Θ value, at 25±0.2°, in an X-ray powder diffraction pattern. The invention also relates to ...
|
|
JP2023527866A |
The present invention relates to means for producing farnesyl dibenzodiazepinone compounds, including AMO-01. [Chemical 1] [Selection drawing] Fig. 1
|
|
JP7299911B2 |
The invention relates to compounds according to the general formula (I) or a pharmaceutically acceptable salt of an inorganic or organic acid, a hydrate, a stereoisomer or a solvate thereof, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 a...
|
|
JP2023523861A |
A salt of a neurotherapeutic agent wherein the neurotherapeutic agent is a substituted benzodiazepine, substituted benzothiazepine, substituted pyridopyrimidine, or substituted amino-cyclohexaneacetic acid and the acid is benzoic acid, n...
|
|
JP2023513731A |
The present invention provides methods of preparing compounds of formula (I), wherein the compounds are represented by the structure of formula (I), wherein R1are each independently F, Cl, Br, I, OCH3, CN or NO2and R2are each independent...
|
|
JP2023512786A |
Provided are compounds of formula (II): or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, and p are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of formu...
|
|
JP2023509496A |
The present invention relates to the technical field of drugs, specifically to RORγt inhibitors, methods for their production and use. Also, a pharmaceutical composition containing the above compound, a method for producing the pharmace...
|
|
JP2023508930A |
The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using them. [Selection figure] None
|
|
JP7228588B2 |
The present invention relates to processes and intermediates useful in the preparation of biologically active molecules, especially in the synthesis of Respiratory Syncytial Virus (RSV) inhibitors. The present invention also relates to p...
|
|
JP7209066B2 |
The present embodiment provides a method for delivering activators to cells, wherein said activator containing lipid particles are brought into contact with the cells,where a compound represented by the formula (1): ...
|
|
JP2022550640A |
Compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein the substituents are as defined herein, are described. Pharmaceutical compositions containing the compounds and methods of using them are also described. [Che...
|
|
JP2022547716A |
Described herein are bifunctional degradation inducer compounds, their various targets, their preparation, pharmaceutical compositions containing them, and their use in the treatment of various target protein-mediated conditions, disease...
|
|
JP7160688B2 |
The present divisional application relates to compounds of formula (II) or salts thereof, pharmaceutical compositions comprising them, and their medical uses. The compounds are inhibitors of CBP and/or EP300 useful for the treatment of v...
|
|
JP7149073B2 |
The present invention describes compounds and uses thereof in applications relating to absorption of electromagnetic energy. Preferred compounds are double bond-containing compounds capable of absorbing electromagnetic radiation energy a...
|
|
JP2022140107A |
To provide a method for efficiently producing a 1,4-benzodiazepine compound without the need for removing a reaction solvent.The present invention discloses a method for producing a 1,4-benzodiazepine compound (2) represented by the foll...
|
|
JP7139323B2 |
The present invention provides compounds that are muscarinic M1 receptor positive allosteric modulators (PAM) and useful in the treatment of diseases, mediated by the muscarinic M1 receptor, such as Alzheimer's disease, cognitive impairm...
|
|
JP7100634B2 |
This invention relates to compounds that are agonists of the muscarinic M1 receptor or M1 and M4 receptors and which are useful in the treatment of muscarinic M1 or M1/M4 receptor mediated diseases. Also provided are pharmaceutical compo...
|
|
JP2022527294A |
The present disclosure relates to therapeutic methods or agents in inflammatory diseases and specific neuropathy associated with inflammatory signaling processes including, but not limited to, compounds, pharmaceutical compositions conta...
|
|
JP7060579B2 |
The invention relates to compounds of formula (I), and pharmaceutical uses thereof. Particular aspects of the invention relate to methods of synthesising the compounds and the use of those compounds in treating, ameliorating, or preventi...
|
|
JP7040819B2 |
Derivatives having the general formula (I) and being limited to structural variants. The claimed compounds are used in the field of medicine as analgesics, anorexigenic or orexigenic agents for regulating weight (loss or gain), antidepre...
|
|
JP6997862B2 |
The present embodiment provides a method for delivering activators to cells, wherein said activator containing lipid particles are brought into contact with the cells,where a compound represented by the formula (1): ...
|
|
JP2022509385A |
The present invention44Sc,47Sc,55Co,62Cu,64Cu,67Cu,66Ga,67Ga,68Ga,89Zr,8
6Y,90Y,90Nb,99mTc,111ln,135Sm,140Pr,159Gd,149Tb,160Tb,161Tb,
165Er,166Dy,166Ho,175Yb,177Lu,186Re,188Re,213Bi and225Ac, or18F,131I or211A chelating agent or fluorina...
|
|
JP2022507335A |
The present disclosure relates to a compound of formula I or a pharmaceutically acceptable salt thereof. Equation (I) is as defined herein. The compound represented by the formula I is pharmacologically effective as a lysyl oxidase (LOX)...
|
|
JP2021534148A |
The present invention is based on the formula (I) :. [Chemical 1]In the formula, Q is selected from O or S and R1And R3Are each independently hydrogen or a hydrocarbyl group optionally substituted, or R1And R3May form an arbitrarily subs...
|
|
JP2021176821A |
To provide a new carotenoid derivative excellent in hydrophilic property and oral absorption.A carotenoid derivative in formula (1) is provided. (in the formula, X represents a carbonyl group or a methylene group, and Z1 and Z2 are the s...
|
|
JP6962572B2 |
[Problem] To provide an agent for inhibiting aggregation of tau and/or amyloid β. [Solution] A compound represented by formula (I) or a salt thereof. This compound is used in therapy, diagnosis, and symptom alleviation and in prevention...
|
|
JP2021121583A |
To provide a new sulfonamide derivative with cholesterol lowering effect, neutral fat reduction effect, and FXR agonist effect that is expected to be effective for treatment of NAFLD and NASH, or a salt thereof, and pharmaceutical compos...
|
|
JP6915056B2 |
A method for predicting a therapeutic effect of a chemotherapy using an antitumor agent comprising an LSD1 inhibitor in a cancer patient based on an expression level of INSM1 in a sample containing tumor cells isolated from the cancer pa...
|
|
JP2021100962A |
To provide imaging technology of animal living brain, and its application.Radiolabeled dibenzoazepine derivatives that exhibit high brain transferability, high receptor selectivity and high quantitation are used for imaging animal organi...
|
|
JP2021514400A |
The present application is a compound having a formula Ia or a formula Ib that regulates the activity of EGFR.Alternatively, the present invention relates to a pharmaceutically acceptable salt, hydrate, or solvate thereof, a pharmaceutic...
|
|
JP6843979B2 |
The present invention provides a compound represented by Formula (I) or a salt thereof; an LSD1 inhibitor that contains the compound or a salt thereof as an active ingredient; a pharmaceutical composition that contains the compound or a ...
|
|
JP2021508737A |
The present invention relates to secondary functional moieties including transition metal based linkers and primary functional moieties attached thereto. The secondary functional moiety according to the present invention comprises a tran...
|
|
JP2021504466A |
The present invention provides compounds that are selective PDE2 inhibitors used in the treatment of tachycardia or tachyarrhythmias. Such compounds are among the following symptoms: atrial tachycardia, atrial fibrillation, atrial flutte...
|
|
JP2021014406A |
To provide a compound that is highly water-soluble and has a vasopressin V2 receptor antagonistic action, which is particularly suitable for parenteral injections, and to provide a pharmaceutical containing said compound.Provided are a c...
|
|
JP6820254B2 |
and to salts thereof, wherein A has any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a...
|
|
JP2021500416A |
The present invention provides a large affinity and activity for the voltage-gated calcium channel (VGCC) subunit α2δ, or a dual activity for the voltage-gated calcium channel (VGCC) subunit α2δ and the noradrenaline transporter (NET...
|
|
JP6789937B2 |
The invention relates to benzodiazepine derivatives of formula (A) useful as CCK2/gastrin receptor antagonists, their preparation and their use in the treatment or prevention of disorders associated with CCK2/gastrin receptors, disorders...
|
|
JP6775803B2 |
The present invention aims to provide a novel low-molecular-weight compound exhibiting an orexin receptor agonist activity and expected to be useful as a prophylactic or therapeutic agent for narcolepsy and the like. The present inventio...
|
|
JP6680683B2 |
Disclosed are compounds of Formula I, or pharmaceutically acceptable salts thereof, wherein W, X, Y, Z, R1, R2, R3, R4 and R5 are as described in this application, and methods of using said compounds in the treatment of cancer.
|
|
JP6668362B2 |
The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I:where R, L, X1, X2, X3, X4, Y1, Y2, Y3,...
|
|
JP6656505B2 |
The invention relates to the field of pharmaceutical chemistry, particularly relates to an orbit azine-fumarate, a hydrate, a crystal form, and a preparation method therefor. Specifically, in the invention, different crystal forms of orb...
|
|
JP2020023446A |
To provide: a method for performing optical carboxylation of o-alkyl benzophenone at a high reaction rate and high yield by a simpler operation; and a method for producing tofisopam at low cost.There is produced 2,3-benzodiazepine deriva...
|
|
JP2020504726A |
As used herein, compounds and methods for inhibiting histone deacetylase (HDAC) enzymes (eg, HDAC1, HDAC2, and HDAC3) are provided.
|
|
JP6600388B2 |
The invention relates to a compound, a tautomer or a stereoisomer of the compound, or a pharmacologically acceptable salt thereof, wherein the compound is selected from the group consisting of the following (1) to (3):(1) 2-(Dimethylamin...
|
|
JP2019167295A |
To provide an industrially advantageous method for producing a calcium salt of 1, 5-benzodiazepine compound in an amorphous form.The present invention provides a method for producing a calcium salt of 1, 5-benzodiazepine compound represe...
|
|
JP6582056B2 |
wherein (R1)n, ring (A), Y1, Y2, X, R4, L1, L2, and A1 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containin...
|
|
JP2019151650A |
To provide compounds for treating viral infections such as hepatitis B, the compounds having allosteric effector properties against hepatitis B virus core protein (Cp) thereby capable of generating defective capsids in viruses.The invent...
|
|
JP2019522633A |
The subjects described herein are directed to antibody-PROTAC conjugates (PACs), pharmaceutical compositions containing them, and their use in the treatment of diseases and conditions in which target proteolysis is beneficial. [Selection...
|
